As part of the study, a screening was performed in C. elegans using Nagi Bioscience’s fully automated high-content screening platform in order to determine the efficacy and necessary dosage of the test compounds.
Our CEO and co-founder, Matteo Cornaglia, speaks today about the future of New Approach Methodologies and how Nagi Bioscience is fulfilling this market need in an interview for Verve Ventures.
Radio Télévision Suisse consulted our co-founder and CSO Laurent Mouchiroud about today’s advances in the field of aging and longevity research for the monthly health reportage.
Our CSO and co-founder Laurent Mouchiroud will present Nagi’s pioneer technology used in a successful project for Bayer CropScience at the prestigious SOT Annual Meeting.
